Prevalence of Atelectasis in Critical Trauma Patients

Pulmonary Atelectasis Clinical Trial

Official title:

The Prevalence and Risk Factors for Lung Atelectasis in Patients With Critical Trauma Who Are Intubated and Mechanically Ventilated

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02739854
• Other study ID #: VHI-prevalence-atelectasis
• Status: Completed
• Phase: N/A
• First received: January 28, 2016
• Last updated: June 2, 2017
• Start date: April 2016
• Est. completion date: May 2017

Study information

• Verified date: June 2017
• Source: Khon Kaen University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The purpose of this study is to identify the prevalence rate and risk factors for pulmonary complications in patients with critical trauma who intubated and mechanical ventilation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 338
• Est. completion date: May 2017
• Est. primary completion date: May 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• An inclusion criterion is the traumatic patients (e.g. head injury, blunt chest, blunt abdomen, and fracture of spine; with or without operative, pure or multitrauma) with intubation and mechanical ventilation who admit at this time period will recruit to the study.

Exclusion Criteria:

• a patients who admit less than 1 day will be excluded such as sudden death or moving to other ward because of improving conditions, etc.

Related Conditions & MeSH terms

• Pulmonary Atelectasis

Locations

Country	Name	City	State
Thailand	Khon Kaen University	Khon Kaen

Sponsors (1)

Lead Sponsor	Collaborator
Khon Kaen University

Country where clinical trial is conducted

Thailand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	number of participants with pulmonary atelectasis		from the date of randomization until the date of first documented of atelectasis, assessed up to 1 years
Secondary	number of participants with pneumonia		from the date of randomization until the date of first documented of pneumonia, assessed up to 1 years
Secondary	number of participants with pleural effusion		from the date of randomization until the date of first documented of pleural effusion, assessed up to 1 years
Secondary	number of participants with abnormal laboratory values	the laboratory test include arterial blood gases (ABG), Clinical chemistry test (i.e. Blood urea nitrogen, Creatinine, Sodium, Potassium, Phosphorus, Chloride, Magnesium).	from the date of randomization until the date of first documented of pleural effusion, assessed up to 1 years
Secondary	number of participants with adverse events that are related to treatment	These data are collected from medical records (i.e. arrhythmia, hypoxia)	from the date of randomization until the date of first documented of pleural effusion, assessed up to 1 years